According to the report, one driver in market is growth of pharmaceutical industry in emerging economies.
The global pharmaceutical industry is undergoing a crisis because of the extensive use of generics, declining investments, change in the reimbursement environment, and strict government regulations on product safety and pricing.
Therefore, pharmaceutical players are exploring alternative routes to improve revenue by shifting their focus toward pharma opportunity-rich regions.
These regions are known as "pharmerging" markets owing to their high growth potential, rising GDP, increasing healthcare spending, availability of cost-efficient resources, and continuously evolving regulatory environments.
Key players in this market include Agilent Technologies, PerkinElmer, Shimadzu and Thermo Fisher Scientific.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA